Findings

What do systematic reviews say?

12 questions · 12 findings · 1 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 8.3%GRADE not reported 3 · 25%Very low 0 · 0%Low 5 · 41.7%Moderate 3 · 25%High 0 · 0%

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Relapse · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Mental state: PANSS responders (ITT data) ‐ medium term PANSS responders‐ participants achieving a >30% improvement in total score · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in mental state: PANSS responders (ITT data) ‐ medium term PANSS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.01 [0.83, 1.23]
2 studies · 1326 participants
Moderate

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Leaving the study early: lack of efficacy ‐ long term · patients with schizophrenia

RISPERIDONE DEPOT may leads to lower leaving the study early: lack of efficacy ‐ long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.6 [0.45, 0.81]
1 study · 749 participants
Low

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Adverse events: Movement disorder requiring the use of anti‐EPS medication ‐ medium term · patients with schizophrenia

RISPERIDONE DEPOT probably leads to higher adverse events: Movement disorder requiring the use of anti‐EPS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.46 [1.18, 1.8]
2 studies · 1666 participants
Moderate

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Weight gain · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 2350 participants
Low

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Adverse events: Any prolactin‐related ‐ medium term · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Any prolactin‐related ‐ medium term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.02 [0.61, 1.71]
2 studies · 1666 participants
Moderate

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Adverse events: Any glucose‐related ‐ medium/long term · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Any glucose‐related ‐ medium/long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.79 [0.89, 3.61]
3 studies · 2413 participants
Low

RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS

Relapse · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS

Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Low

RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher leaving the study early for any reason ‐ long term compared with TYPICAL DEPOT ANTIPSYCHOTICS (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 3.05 [1.12, 8.31]
1 study · 62 participants
Low

RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS

Adverse events: General: Severe adverse event · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS

Adverse events: related to movement disorder, weight gain, prolactin levels and glucose metabolism ‐ medium/long term ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found